|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ATP5C1 |
Gene summary for ATP5C1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ATP5C1 | Gene ID | 509 |
| Gene name | ATP synthase F1 subunit gamma | |
| Gene Alias | ATP5C | |
| Cytomap | 10p14 | |
| Gene Type | protein-coding | GO ID | GO:0006091 | UniProtAcc | P36542 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 509 | ATP5C1 | Pat18-B | Human | Stomach | GC | 1.29e-18 | -7.54e-01 | -0.0432 |
| 509 | ATP5C1 | Pat19-B | Human | Stomach | GC | 9.84e-14 | -7.54e-01 | 0.0826 |
| 509 | ATP5C1 | Pat22-B | Human | Stomach | GC | 3.87e-17 | -7.54e-01 | -0.1042 |
| 509 | ATP5C1 | Pat24-B | Human | Stomach | GC | 8.86e-11 | -7.54e-01 | -0.1184 |
| 509 | ATP5C1 | Pat25-A | Human | Stomach | CAG with IM | 1.09e-26 | -7.54e-01 | -0.1648 |
| 509 | ATP5C1 | Pat26-A | Human | Stomach | CSG | 1.59e-22 | -7.54e-01 | -0.2402 |
| 509 | ATP5C1 | Pat28-A | Human | Stomach | CSG | 1.09e-10 | -7.54e-01 | -0.2594 |
| 509 | ATP5C1 | Pat29-A | Human | Stomach | CAG with IM | 2.13e-03 | -7.54e-01 | -0.2769 |
| 509 | ATP5C1 | CAG_3 | Human | Stomach | CAG | 1.61e-06 | -4.45e-01 | -0.2766 |
| 509 | ATP5C1 | SIM_2 | Human | Stomach | SIM | 9.69e-08 | -2.81e-01 | 0.3139 |
| 509 | ATP5C1 | Adj_PTCwithHT_6 | Human | Thyroid | HT | 4.62e-14 | -5.71e-01 | 0.02 |
| 509 | ATP5C1 | PTCwithHT_6 | Human | Thyroid | HT | 9.10e-06 | -4.65e-01 | 0.02 |
| 509 | ATP5C1 | PTCwithHT_8 | Human | Thyroid | HT | 9.86e-07 | -4.94e-01 | 0.0351 |
| 509 | ATP5C1 | PTCwithoutHT_2 | Human | Thyroid | PTC | 8.85e-06 | -4.38e-01 | 0.0419 |
| 509 | ATP5C1 | male-WTA | Human | Thyroid | PTC | 4.42e-19 | -6.88e-01 | 0.1037 |
| 509 | ATP5C1 | female-WTA | Human | Thyroid | PTC | 4.68e-05 | -6.88e-01 | 0.0726 |
| 509 | ATP5C1 | nodule-WTA | Human | Thyroid | goiters | 1.56e-12 | -6.88e-01 | 0.0534 |
| 509 | ATP5C1 | PTC01 | Human | Thyroid | PTC | 1.02e-18 | -6.88e-01 | 0.1899 |
| 509 | ATP5C1 | PTC03 | Human | Thyroid | PTC | 1.37e-03 | -6.88e-01 | 0.1784 |
| 509 | ATP5C1 | PTC04 | Human | Thyroid | PTC | 3.57e-20 | -6.88e-01 | 0.1927 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0501218 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
| hsa0502016 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
| hsa0501616 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
| hsa0019016 | Breast | Precancer | Oxidative phosphorylation | 59/684 | 134/8465 | 6.15e-30 | 3.24e-28 | 2.48e-28 | 59 |
| hsa0501016 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
| hsa0501416 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
| hsa0502216 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
| hsa0520818 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
| hsa0471418 | Breast | Precancer | Thermogenesis | 68/684 | 232/8465 | 4.40e-22 | 1.26e-20 | 9.69e-21 | 68 |
| hsa0541518 | Breast | Precancer | Diabetic cardiomyopathy | 63/684 | 203/8465 | 5.63e-22 | 1.48e-20 | 1.14e-20 | 63 |
| hsa0501219 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
| hsa0502017 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
| hsa0501617 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
| hsa0019017 | Breast | Precancer | Oxidative phosphorylation | 59/684 | 134/8465 | 6.15e-30 | 3.24e-28 | 2.48e-28 | 59 |
| hsa0501017 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
| hsa0501417 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
| hsa0502217 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
| hsa0520819 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
| hsa0471419 | Breast | Precancer | Thermogenesis | 68/684 | 232/8465 | 4.40e-22 | 1.26e-20 | 9.69e-21 | 68 |
| hsa0541519 | Breast | Precancer | Diabetic cardiomyopathy | 63/684 | 203/8465 | 5.63e-22 | 1.48e-20 | 1.14e-20 | 63 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ATP5C1 | SNV | Missense_Mutation | c.196N>T | p.Ala66Ser | p.A66S | P36542 | protein_coding | deleterious(0.02) | possibly_damaging(0.829) | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ATP5C1 | SNV | Missense_Mutation | novel | c.361C>A | p.Leu121Ile | p.L121I | P36542 | protein_coding | tolerated(0.19) | benign(0.027) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ATP5C1 | SNV | Missense_Mutation | novel | c.323C>T | p.Ser108Phe | p.S108F | P36542 | protein_coding | deleterious(0.03) | benign(0.239) | TCGA-EW-A6SA-01 | Breast | breast invasive carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| ATP5C1 | SNV | Missense_Mutation | novel | c.817N>G | p.Leu273Val | p.L273V | P36542 | protein_coding | deleterious(0.02) | possibly_damaging(0.467) | TCGA-OL-A5RZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
| ATP5C1 | SNV | Missense_Mutation | novel | c.714C>G | p.Ile238Met | p.I238M | P36542 | protein_coding | deleterious(0.02) | possibly_damaging(0.852) | TCGA-VS-A9UL-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD |
| ATP5C1 | SNV | Missense_Mutation | rs200847831 | c.829N>T | p.Arg277Cys | p.R277C | P36542 | protein_coding | tolerated(0.06) | possibly_damaging(0.524) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| ATP5C1 | SNV | Missense_Mutation | c.809N>G | p.Lys270Arg | p.K270R | P36542 | protein_coding | tolerated(0.12) | benign(0.076) | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD | |
| ATP5C1 | SNV | Missense_Mutation | novel | c.518N>C | p.Leu173Ser | p.L173S | P36542 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| ATP5C1 | SNV | Missense_Mutation | novel | c.76N>A | p.Ala26Thr | p.A26T | P36542 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| ATP5C1 | SNV | Missense_Mutation | rs758013111 | c.497C>T | p.Ala166Val | p.A166V | P36542 | protein_coding | tolerated(0.1) | benign(0.399) | TCGA-EI-6882-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |